You are here

  • Home
  • Archive
  • Volume 81, Issue 7
  • Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Article metrics

Article menu
Systemic lupus erythematosus
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

 

Online download statistics by month:

Online download statistics by month: March 2022 to March 2024

AbstractFullPdf
Mar 2022822813405
Apr 202214251421589
May 2022885884327
Jun 202210181008387
Jul 2022821831261
Aug 2022374373194
Sep 2022462462202
Oct 2022334333150
Nov 2022299295145
Dec 2022225220126
Jan 2023297293171
Feb 2023278258122
Mar 2023293264141
Apr 2023363365138
May 2023274257110
Jun 2023218195112
Jul 2023170146115
Aug 202316614684
Sep 202317214493
Oct 2023297279109
Nov 2023275239121
Dec 2023269234149
Jan 2024324266145
Feb 202448119399
Mar 2024319307131
Total10861102264626